I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2025 Q2, the actual value is USD 31.66 M, beating the estimate of USD 16.73 M.
EPS: As of FY2025 Q2, the actual value is USD -0.79, beating the estimate of USD -0.9521.
Segment Revenue
- Collaboration revenue from ZURZUVAE was $23.2 million in the second quarter of 2025, representing a 68% increase from the first quarter of 2025 and a significant increase from $7.4 million in the same period in 2024.
- Other collaboration revenue was $8.5 million in the second quarter of 2025 compared to $0.6 million for the same period in 2024.
Operational Metrics
- Cost of revenues was -$0.1 million in the second quarter of 2025, compared to $1.4 million for the same period in 2024.
- Research and development expenses were $23.7 million in the second quarter of 2025, down from $62.6 million in the same period in 2024.
- Selling, general and administrative expenses were $62.0 million in the second quarter of 2025, up from $56.0 million in the same period in 2024.
- Net loss was $49.7 million for the second quarter of 2025 compared to $102.9 million for the same period in 2024.
Cash Flow
- Cash, cash equivalents, and marketable securities were $366 million as of June 30, 2025, compared to $424 million at March 31, 2025.
Unique Metrics
- Greater than 4,000 prescriptions of ZURZUVAE were shipped to women with postpartum depression in the second quarter of 2025, representing a 36% increase from the first quarter of 2025.
Outlook / Guidance
- Sage Therapeutics anticipates significant topline revenue growth in 2025 due to increased commercialization investments for ZURZUVAE.
- The acquisition by Supernus Pharmaceuticals is expected to close in the third quarter of 2025, with a tender offer of $8.50 per share in cash plus contingent value rights worth up to $3.50 per share.
- Sage plans to continue exploring its NMDA receptor negative allosteric modulator platform for potential treatments for neurodevelopmental disorders.